Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exec Chat: Sequana Medical Pursues Dual Device-Drug Strategy For Fluid Overload

Executive Summary

Speaking to Medtech Insight, Sequana Medical’s CEO discussed the company’s two technologies for combating fluid overload whilst explaining that, sometimes, chasing approval as a drug can be the best way to ensure easy market access.

You may also be interested in...



Fancy Making A Drug? You May Want To Create A Diagnostic First.

Ochre Bio co-founder and CEO, Jack O’Meara, spoke to Medtech Insight about the company’s human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how a fledgling drug company's early work can mirror that seen in diagnostics.

Exec Chat: Catching Up With Drug-Device Developers Sequana At LSX

The company’s dual drug-device development pipeline is progressing well, with the company expecting its device, the Alfapump, to hit US clinics in 2025.

Talking Trials, Investment And Fluid-Overload Treatments With Sequana Medical

Sequana Medical is simultaneously developing both drug and device treatments for fluid overloads in the body. Medtech Insight spoke to the company’s CEO about their trials and the challenges of raising cash in 2023.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel